Int J Oral Implantol (Berl). 2024 May 27;17(2):137-161.
To provide an overview of the outcomes of the use of autogenous platelet concentrates in immediate implant placement.
Based on an a priori protocol, a systematic search was performed of the National Library of Medicine (MEDLINE via PubMed), Embase and Scopus databases. Randomised and non-randomised controlled clinical trials on immediate implant placement including at least one study arm with use of platelet-rich fibrin or platelet-rich plasma as a gap filler between immediately placed implants and the alveolar bone were included. A random-effects meta-analysis model was built to assess the primary outcomes of marginal bone loss and probing pocket depths between test (platelet concentrates) and control (no graft or other graft materials) groups. A risk of bias assessment was performed and the Grading of Recommendations Assessment, Development and Evaluation approach was used to assess the certainty of evidence.
A total of 20 trials (595 immediate implants placed in 454 individuals) were included in the meta-analytic model. Based on the data from studies with a minimum post-prosthetic loading period of 6 months after immediate implant placement, overall, the application of platelet concentrates was associated with significantly lower marginal bone loss and probing pocket depth compared to the control groups (mean difference -0.36 mm; P < 0.01 and mean difference -0.47 mm; P < 0.01, respectively). No additional benefit of application of platelet concentrates was detected regarding primary stability of immediate implants. Subgroup analysis revealed significantly lower marginal bone loss with xenogeneic bone alone compared to platelet concentrates alone as grafting material in immediate implant placement (mean difference 0.66 mm; P < 0.01). Evidence on soft tissue outcomes and aesthetic parameters was scarce.
A low level of certainty based on the Grading of Recommendations Assessment, Development and Evaluation approach indicates superior outcomes in terms of marginal bone loss and probing pocket depth in immediate implant placement with the use of platelet concentrates versus no graft. Future research should be tailored towards a standardised protocol for preparation of platelet concentrates and inclusion of soft tissue and aesthetic outcomes as well.
提供自体血小板浓缩物在即刻种植体植入中应用效果的概述。
根据预先制定的方案,对美国国立医学图书馆(通过 PubMed 检索 MEDLINE)、Embase 和 Scopus 数据库进行了系统性检索。纳入了即刻种植体植入中包含富血小板纤维蛋白或富血小板血浆作为即刻放置的种植体与牙槽骨之间的间隙填充物的至少一个研究臂的随机和非随机对照临床试验。建立了随机效应荟萃分析模型,以评估测试(血小板浓缩物)和对照组(无移植物或其他移植物材料)之间边缘骨丢失和探诊袋深度的主要结果。进行了偏倚风险评估,并使用推荐评估、制定和评估方法(Grading of Recommendations Assessment, Development and Evaluation approach)评估证据的确定性。
共有 20 项试验(454 名个体中放置了 595 个即刻种植体)纳入荟萃分析模型。基于即刻种植体放置后至少 6 个月进行修复后即刻种植体的研究数据,总体而言,与对照组相比,血小板浓缩物的应用与较低的边缘骨丢失和探诊袋深度相关(平均差异-0.36mm;P<0.01 和平均差异-0.47mm;P<0.01)。未发现即刻种植体应用血小板浓缩物对其初期稳定性有额外益处。亚组分析显示,与单独使用血小板浓缩物作为移植物材料相比,单独使用异种骨作为移植物材料在即刻种植体植入中具有更低的边缘骨丢失(平均差异 0.66mm;P<0.01)。关于软组织结果和美学参数的证据很少。
根据推荐评估、制定和评估方法(Grading of Recommendations Assessment, Development and Evaluation approach),低确定性水平表明,与不使用移植物相比,使用血小板浓缩物进行即刻种植体植入在边缘骨丢失和探诊袋深度方面具有更好的效果。未来的研究应针对血小板浓缩物的制备标准化方案以及包括软组织和美学结果进行调整。